SAINT LAURENT, QUEBEC--(Marketwire - May 17, 2010) - IntelGenx Technologies Corp. ("IntelGenx") (TSX VENTURE:IGX)(OTCBB:IGXT) announced today that the Company's board of directors granted options to acquire 75,000 common shares effective May 17, 2010 to one of the Company's non employee directors, Mr. Bernd Melchers. The options were granted under the 2006 Stock Option Plan with an exercise price of C$0.47, vest immediately, and expire in five years.
About IntelGenx Corp.
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis and depressive disorders. More information is available about the company at www.intelgenx.com
The TSX Venture Exchange and OTC Bulletin Board have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.